| Amy Jo Schmoll, CRNA | |
|
171 Ashley Ave, Charleston, SC 29425-0001 | |
| (843) 792-1414 | |
| Not Available |
| Full Name | Amy Jo Schmoll |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 18 Years |
| Location | 171 Ashley Ave, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245364132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 3119 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical University Hospital Authority | 1557268950 | 171 |
News Archive
A study of a new mouse model identifies a drug target that has the potential to increase social interaction in individuals with some forms of autism spectrum disorder (ASD), according to researchers in the Perelman School of Medicine at the University of Pennsylvania. The team published their work in Biological Psychiatry.
OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),
Researchers at the U.S. Department of Energy's Brookhaven National Laboratory have developed an imaging protocol that allows them to visualize the activity of the brain's reward circuitry in both normal individuals and those addicted to drugs. The technique could lead to better insight into why people take recreational drugs as well as help determine which treatment strategies might be most effective.
HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases.
A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.
› Verified 9 days ago
| Entity Name | Medical University Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255305876 PECOS PAC ID: 1557268950 Enrollment ID: O20031215000499 |
News Archive
A study of a new mouse model identifies a drug target that has the potential to increase social interaction in individuals with some forms of autism spectrum disorder (ASD), according to researchers in the Perelman School of Medicine at the University of Pennsylvania. The team published their work in Biological Psychiatry.
OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),
Researchers at the U.S. Department of Energy's Brookhaven National Laboratory have developed an imaging protocol that allows them to visualize the activity of the brain's reward circuitry in both normal individuals and those addicted to drugs. The technique could lead to better insight into why people take recreational drugs as well as help determine which treatment strategies might be most effective.
HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases.
A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.
› Verified 9 days ago
| Entity Name | Anesthesia Care Services Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609833474 PECOS PAC ID: 7012937105 Enrollment ID: O20160627002393 |
News Archive
A study of a new mouse model identifies a drug target that has the potential to increase social interaction in individuals with some forms of autism spectrum disorder (ASD), according to researchers in the Perelman School of Medicine at the University of Pennsylvania. The team published their work in Biological Psychiatry.
OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),
Researchers at the U.S. Department of Energy's Brookhaven National Laboratory have developed an imaging protocol that allows them to visualize the activity of the brain's reward circuitry in both normal individuals and those addicted to drugs. The technique could lead to better insight into why people take recreational drugs as well as help determine which treatment strategies might be most effective.
HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases.
A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Jo Schmoll, CRNA Po Box 751461, Charlotte, NC 28275-1461 Ph: (843) 792-6200 | Amy Jo Schmoll, CRNA 171 Ashley Ave, Charleston, SC 29425-0001 Ph: (843) 792-1414 |
News Archive
A study of a new mouse model identifies a drug target that has the potential to increase social interaction in individuals with some forms of autism spectrum disorder (ASD), according to researchers in the Perelman School of Medicine at the University of Pennsylvania. The team published their work in Biological Psychiatry.
OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),
Researchers at the U.S. Department of Energy's Brookhaven National Laboratory have developed an imaging protocol that allows them to visualize the activity of the brain's reward circuitry in both normal individuals and those addicted to drugs. The technique could lead to better insight into why people take recreational drugs as well as help determine which treatment strategies might be most effective.
HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases.
A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.
› Verified 9 days ago
Christopher Arnold Hensley, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Linda G Dancy, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Sallie B Beam, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 9263 Medical Plaza Dr, Ste E, Charleston, SC 29406 Phone: 843-572-1228 Fax: 877-561-7564 | |
Ginger L Brister, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2095 Henry Tecklenburg Dr, Charleston, SC 29414 Phone: 843-876-5746 | |
Mrs. Tammie Ann Stahl, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2095 Henry Tecklenburg Dr, Charleston, SC 29414 Phone: 843-402-1436 Fax: 843-402-1833 | |
Helen E Harman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Annette W Cooper, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 9326 Medical Plaza Dr, Ste B, Charleston, SC 29406 Phone: 843-553-7070 Fax: 843-553-2223 |